Concert Pharma (CNCE) Announces $65M Institutional Financing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/11/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- Wall Street ends higher as investors turn to earnings season
- AppLovin gains market share among e-commerce advertisers
Concert Pharmaceuticals Announces $65 Million Financing
November 4, 2021 7:00 AM EDTFinancing Provided by Leading Healthcare Funds BVF Partners L.P. and RA Capital Management
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has entered into an agreement with BVF Partners L.P. (BVF) and RA Capital Management (RA) to raise gross proceeds of $65 million. In addition, Concert will have the potential to receive an additional $103 million upon the full exercise of warrants being issued in connection with the agreement. Closing of the financing is expected on or about November 5, 2021.... More
